Program Information

End to End Testing of a Prototype Eclipse Module for Planning Modulated Arc Therapy On the Siemens Platform

L Huang

L Huang¹*, V Sarkar² , S Spiessens³ , P Rassiah-Szegedi⁴ , Y Huang⁵ , H Zhao⁶ , M Szegedi⁷ , B Salter⁸ , (1) Huntsman Cancer Hospital, Salt Lake City, UT, (2) Univ of Utah Hospitals, Salt Lake City, UT, (3) Varian Medical Systems France, Buc Cedex, France, (4) University Utah, Salt Lake City, UT, (5) University Utah, Salt Lake City, UT, (6) Univ of Utah , Salt Lake City, UT, (7) Huntsman Cancer Hospital, The University of Utah, Salt Lake City, UT, (8) University Utah, Salt Lake City, UT

Presentations

SU-E-T-508 Sunday 3:00PM - 6:00PM Room: Exhibit Hall

Purpose:
The latest clinical implementation of the Siemens Artiste linac allows for delivery of modulated arcs (mARC) using full-field flattening filter free (FFF) photon beams. The maximum doserate of 2000 MU/min is well suited for high dose treatments such as SBRT. We tested and report on the performance of a prototype Eclipse TPS module supporting mARC capability on the Artiste platform.
Method:
Four spine SBRT patients originally treated with 12/13 field static-gantry IMRT (SGIMRT) were chosen for this study. These plans were designed to satisfy RTOG0631 guidelines with a prescription of 16Gy in a single fraction. The cases were re-planned as mARC plans in the prototype Eclipse module using the 7MV FFF beam and required to satisfy RTOG0631 requirements. All plans were transferred from Eclipse, delivered on a Siemens Artiste linac and dose-validated using the Delta4 system.
Results:
All treatment plans were straightforwardly developed, in timely fashion, without challenge or inefficiency using the prototype module. Due to the limited number of segments in a single arc, mARC plans required 2-3 full arcs to yield plan quality comparable to SGIMRT plans containing over 250 total segments. The average (3%/3mm) gamma pass-rate for all arcs was 98.5±1.1%, thus demonstrating both excellent dose prediction by the AAA dose algorithm and excellent delivery fidelity. Mean delivery times for the mARC plans(10.5±1.7min) were 50-70% lower than the SGIMRT plans(26±2min), with both delivered at 2000 MU/min.
Conclusion:
A prototype Eclipse module capable of planning for Burst Mode modulated arc delivery on the Artiste platform has been tested and found to perform efficiently and accurately for treatment plan development and delivered-dose prediction. Further investigation of more treatment sites is being carried out and data will be presented.




Contact Email: